中华核医学与分子影像杂志
中華覈醫學與分子影像雜誌
중화핵의학여분자영상잡지
Chinese Journal of Nuclear Medicine and Molecular Imaging
2013年
4期
243-247
,共5页
石亮荣%吴骏%周文杰%黄渊全%李忠%季枚%张红宇%赵洁敏%蒋敬庭
石亮榮%吳駿%週文傑%黃淵全%李忠%季枚%張紅宇%趙潔敏%蔣敬庭
석량영%오준%주문걸%황연전%리충%계매%장홍우%조길민%장경정
胃肿瘤%淋巴转移%近距离放射疗法%碘放射性同位素%体层摄影术,X线计算机
胃腫瘤%淋巴轉移%近距離放射療法%碘放射性同位素%體層攝影術,X線計算機
위종류%림파전이%근거리방사요법%전방사성동위소%체층섭영술,X선계산궤
Stomach neoplasms%Lymphatic metastasis%Brachytherapy%Iodine radioisotopes%Tomography,X-ray computed
目的 评价CT引导125I粒子植入术治疗胃癌术后区域淋巴结转移的安全性与近期疗效.方法 对23例胃癌术后局限性区域淋巴结转移并接受CT引导125I粒子植入治疗患者的临床病理特征与生存资料进行回顾性分析.所有患者术前经放射性粒子植入计划系统模拟布源,计算放射性粒子总活度与粒子数量.CT引导下经皮穿刺植入125I粒子.术后2个月参照实体瘤疗效评价标准(RECIST)评价近期疗效,采用寿命表法计算植入术后患者1、2和3年生存率；以单变量Cox模型检验相关因素对生存的影响；采用log-rank法比较组间(肿瘤最大径＞3 cm组和＜3 cm组)生存差异并绘制生存曲线.20例患者粒子植入术后接受了以氟尿嘧啶类药物为基础的全身化疗.结果 23例患者均未出现严重并发症.CR 14例(60.9％,14/23),PR 5例(21.7％,5/23),PD 4例(17.4％,4/23).患者粒子植入术后1、2和3年生存率分别为(87±7)％、(47±11)％与(13±9)％,中位生存时间为(22.1±5.1)个月.单变量Cox分析,肿瘤最大径是影响生存时间的因素(x2=9.752,P=0.002),＞3 cm组和＜3 cm组的中位生存时间分别为(17.0±5.0)和(30.0±5.1)个月,2组总生存时间差异具有统计学意义(x2=5.828,P=0.016).结论 CT引导1251粒子植入术治疗胃癌术后局限性区域淋巴结转移创伤小且并发症少,并能取得较高的局部控制率.
目的 評價CT引導125I粒子植入術治療胃癌術後區域淋巴結轉移的安全性與近期療效.方法 對23例胃癌術後跼限性區域淋巴結轉移併接受CT引導125I粒子植入治療患者的臨床病理特徵與生存資料進行迴顧性分析.所有患者術前經放射性粒子植入計劃繫統模擬佈源,計算放射性粒子總活度與粒子數量.CT引導下經皮穿刺植入125I粒子.術後2箇月參照實體瘤療效評價標準(RECIST)評價近期療效,採用壽命錶法計算植入術後患者1、2和3年生存率；以單變量Cox模型檢驗相關因素對生存的影響；採用log-rank法比較組間(腫瘤最大徑＞3 cm組和＜3 cm組)生存差異併繪製生存麯線.20例患者粒子植入術後接受瞭以氟尿嘧啶類藥物為基礎的全身化療.結果 23例患者均未齣現嚴重併髮癥.CR 14例(60.9％,14/23),PR 5例(21.7％,5/23),PD 4例(17.4％,4/23).患者粒子植入術後1、2和3年生存率分彆為(87±7)％、(47±11)％與(13±9)％,中位生存時間為(22.1±5.1)箇月.單變量Cox分析,腫瘤最大徑是影響生存時間的因素(x2=9.752,P=0.002),＞3 cm組和＜3 cm組的中位生存時間分彆為(17.0±5.0)和(30.0±5.1)箇月,2組總生存時間差異具有統計學意義(x2=5.828,P=0.016).結論 CT引導1251粒子植入術治療胃癌術後跼限性區域淋巴結轉移創傷小且併髮癥少,併能取得較高的跼部控製率.
목적 평개CT인도125I입자식입술치료위암술후구역림파결전이적안전성여근기료효.방법 대23례위암술후국한성구역림파결전이병접수CT인도125I입자식입치료환자적림상병리특정여생존자료진행회고성분석.소유환자술전경방사성입자식입계화계통모의포원,계산방사성입자총활도여입자수량.CT인도하경피천자식입125I입자.술후2개월삼조실체류료효평개표준(RECIST)평개근기료효,채용수명표법계산식입술후환자1、2화3년생존솔；이단변량Cox모형검험상관인소대생존적영향；채용log-rank법비교조간(종류최대경＞3 cm조화＜3 cm조)생존차이병회제생존곡선.20례환자입자식입술후접수료이불뇨밀정류약물위기출적전신화료.결과 23례환자균미출현엄중병발증.CR 14례(60.9％,14/23),PR 5례(21.7％,5/23),PD 4례(17.4％,4/23).환자입자식입술후1、2화3년생존솔분별위(87±7)％、(47±11)％여(13±9)％,중위생존시간위(22.1±5.1)개월.단변량Cox분석,종류최대경시영향생존시간적인소(x2=9.752,P=0.002),＞3 cm조화＜3 cm조적중위생존시간분별위(17.0±5.0)화(30.0±5.1)개월,2조총생존시간차이구유통계학의의(x2=5.828,P=0.016).결론 CT인도1251입자식입술치료위암술후국한성구역림파결전이창상소차병발증소,병능취득교고적국부공제솔.
Objective To evaluate the safety and short term effect of 125I seed implantation for locoregional lymph node metastases in patients with recurrent gastric cancer.Methods The data of 23 gastric cancer patients with locoregional lymph node metastases treated by CT-guided 125I seed implantation were retrospectively studied.Patient characteristics and survival data were collected and analyzed.The procedure for seed implantation was performed under CT guidance according to preoperative treatment planning.Evaluation of short-term effect was carried out two months after the 125I seed implantation using response evaluation criteria in solid tumors (RECIST).The 1-,2-and 3-year survival rates were plotted using the life table method.The potential predictors of survival were tested using univariate Cox models.Log-rank method was used to test the difference of survival in subgroups with tumor size ＞3 cm and ＜3 cm.Twenty patients underwent fluoropyrimidine-based chemotherapy after 125I seed implantation.Results None of the 23 patients had serious complications.Two months after 125I seed implantation,the CR,PR and PD rates were 60.9％ (14/23),21.7％ (5/23) and 17.4％ (4/23),respectively.The median survival time was (22.1±5.1) months,and the 1-,2-,3-year survival rates were (87±7) ％,(47± 11) ％ and (13 ±9) ％,respectively.The tumor size (longest diameter) was the most significant factor for prognosis (x2=9.752,P=0.002).Patients with tumor ＜3 cm in diameter had longer survival time than those with tumor ＞3 cm ((30.0±5.1) vs (17.0±5.0) months;x2 =5.828,P=0.016).Conclusion CT-guided brachytherapy using 125I seed implantation is a safe and effective method for palliative treatment of locoregional lymph node metastases for recurrent gastric cancer.
